Verified employee & interview reviews

Aurobindo Pharma Reviews

Hyderabad, Telangana

4.0/ 5

2 reviews

Aurobindo Pharma Limited is a prominent Indian multinational pharmaceutical manufacturing company headquartered in Hyderabad, Telangana, India. Founded in 1986 by Mr. P.V. Ramprasad Reddy, Mr. K. Nityananda Reddy, and a dedicated group of professionals, the company began its commercial operations in 1988–89 with a single unit manufacturing semi-synthetic penicillin (SSP) in Puducherry. Aurobindo Pharma transitioned into a public entity in 1992 and officially listed its shares on the Indian stock exchanges in 1995. Over the decades, it has evolved from an initial supplier of active pharmaceutical ingredients (APIs) into a major global force in both APIs and finished dosage generic formulations. Today, Aurobindo Pharma ranks as India's second-largest listed pharmaceutical company by revenue and holds a commanding position globally. It stands as the largest generics company in the United States by volume and features among the top ten generic companies across multiple European countries, including the United Kingdom, Germany, and Spain. The company's extensive geographic footprint allows it to market and distribute high-quality, affordable medicines to patients in over 150 countries worldwide, with a significant portion of its total consolidated revenues derived from its international operations, particularly within the regulated markets of the US and Europe. The core business operations of Aurobindo Pharma encompass the development, manufacturing, and commercialization of a diverse product portfolio across key therapeutic segments. These include antibiotics, anti-retrovirals, cardiovascular products, central nervous system (CNS) therapies, gastroenterologicals, anti-allergics, anti-diabetics, and dermatology. Structurally, the company operates 29 state-of-the-art manufacturing and packaging facilities globally, which maintain robust compliance and approvals from stringent international regulatory bodies, including the USFDA, UK MHRA, Health Canada, and ANVISA Brazil. These facilities boast a massive collective capacity, producing over 50 billion formulation units and more than 19,000 metric tons of APIs annually. Aurobindo is heavily committed to innovation, supported by nine advanced Research and Development centers staffed by over 1,500 scientists. This strong scientific foundation has enabled the company to become one of the highest global filers of Drug Master Files (DMFs) and build a massive pipeline, including over 830 Abbreviated New Drug Application (ANDA) filings in the United States alone. Strategically moving forward, Aurobindo Pharma is rapidly expanding into complex, high-value segments. Through strategic acquisitions, such as its recent $250 million purchase of Lannett Company in 2026, and its dedicated biologics subsidiary TheraNym Biologics, the company is scaling up operations in oncology, biosimilars, respiratory therapies, depot injections, and contract manufacturing (CDMO) partnerships. Led by Vice Chairman and Managing Director K. Nityananda Reddy, Aurobindo continues to champion global health equity by rendering essential medicines accessible and affordable.